Papers
8
Total Citations
110
H-Index
3
About
Mir Imran is a pioneering biomedical engineer and inventor whose research focuses on transforming the delivery of biotherapeutics through innovative oral technologies. His major contribution is the development of an orally ingestible robotic pill that safely and effectively delivers large-molecule drugs—such as antibodies, peptides, and hormones—that traditionally require painful injections. This breakthrough addresses a critical challenge: the degradation of biotherapeutics in the gastrointestinal tract. Imran’s most-cited work, a 2021 study on the robotic pill’s safety and tolerability in healthy subjects (94 citations), demonstrated its potential to improve patient compliance for chronic conditions. Subsequent studies showed high bioavailability of antibodies and teriparatide in both canines and humans, rivaling parenteral administration. His phase 1 trials confirmed reliable delivery of osteoanabolic agents for osteoporosis and GLP-1 agonists for diabetes, with bioavailability far exceeding oral alternatives. Imran’s work has profound implications for conditions requiring chronic injections, from osteoporosis to metabolic disorders. As founder of Rani Therapeutics, he continues to advance this platform, with multiple clinical trials underway. His inventions have earned him over 200 patents and recognition as a National Academy of Engineering member, cementing his legacy in drug delivery innovation.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8